Results 91 to 100 of about 66,826 (280)

Intraosseous sarcoidosis imitating peri‐implantitis: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska, David S. Gottlieb, Kenneth S. Kornman   +2 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Relentless Placoid Chorioretinitis: A Case Series of Successful Tapering of Systemic Immunosuppressants Achieved with Adalimumab

Case Reports in Ophthalmology, 2019
Background: Adalimumab, a human anti-tumor necrosis factor-ɑ monoclonal antibody, was recently reported to be effective in lowering the risk of recurrence of noninfectious uveitis.
Shotaro Asano, Rie Tanaka, Hidetoshi Kawashima, Toshikatsu Kaburaki   +3 more
doaj   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Adalimumab Monotherapy in a Patient with Psoriatic Arthritis Associated with Chronic Renal Failure on Hemodialysis: A Case Report and Literature Review

Clinical Medicine Insights: Case Reports, 2012
We report a patient with psoriatic arthritis (PsA) who was successfully treated with adalimumab even while under hemodialysis therapy for associated chronic renal failure. Flow cytometry of circulating lymphocytes revealed an obvious decrease in both Th1
Yasuhiro Shimojima, Masayuki Matsuda, Wataru Ishii, Shu-ichi Ikeda   +3 more
doaj   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

Clinical Pharmacology &Therapeutics, EarlyView.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo, Sarah N. Hilmer, David J. Hunter, Stephanie Mathieson, Riyaas Mohamed, Leo Li, Natalie Fung, Anthony Yue, Manuela L. Ferreira   +8 more
wiley   +1 more source

The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients

Frontiers in Immunology
Treatment efficacy of patients receiving anti-TNF antibodies is limited by the formation of anti-drug antibodies. These are observed in most adalimumab-treated rheumatoid arthritis patients, despite the adjuvant-free and human sequence-derived nature of ...
Mateusz Makuch, Josine van Beek, Josine van Beek, Carla A. Wijbrandts, Marja Aalbers, Philippe Stas, Alexander B. Meijer, Anja ten Brinke, Theo Rispens, Paul Peter Tak, Paul Peter Tak, Gertjan Wolbink, Gertjan Wolbink, Janine Schuurman, Paul W. H. I. Parren, Paul W. H. I. Parren, S. Marieke van Ham, S. Marieke van Ham   +17 more
doaj   +1 more source

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

A Review of Ankylosing Spondylitis [PDF]

, 2017
Ankylosing spondylitis (AS) is a systemic autoimmune disorder that induces ankylosis of the spine (fusion of the vertebrae at their various joints) and inflammatory arthritis of peripheral joints among other symptoms.
Owen, Hannah L
core   +1 more source

Precision Imaging for Optimized Crohn's Disease Management: Navigating the Evolution of Objective Healing Goals

iRADIOLOGY, EarlyView.
Multimodal imaging enables the transition to transmural healing as a superior therapeutic target in Crohn's disease, facilitating precise stricture characterization and the prediction of long‐term clinical outcomes. Some icons are sourced from Figdraw and have been authorized (ID: ROSUUdd4c2).
Ziman Xiong, Yufan Wang, Shuxin Luo, Zhen Li, Yaqi Shen   +4 more
wiley   +1 more source